Fig. 1: Response to Birinapant treatments in colon cancer cell lines.
From: Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant
A HCT116, LS1034, LS513, and MDST8 cells were treated for 24 h and 48 h with the indicated treatments. The colored bars represent the subtype of the cell lines (CMS1—orange; CMS2—blue; CMS3—pink; CMS4—green). Blots were probed for cIAP1, cIAP2, and XIAP as well as the cleaved forms of caspase-3, -7, and -8. B–D All cell lines were treated for 48 h with 10 ng/ml TNFα, 1 µM Birinapant, 2 µM oxaliplatin/ 10 µM 5-FU (Oxa/5-FU) or a combination of these drugs. B Gating strategy for apoptosis assay. Only the sum of necrotic, early-, and late-apoptotic cells are shown in C and D. C Combined treatment results of all cell lines by CMS subtype. To normalize cell line intrinsic cell death, the background cell death (DMSO control) was subtracted. A two-way ANOVA was performed, excluding the CMS4 subtype. A Tukey’s test for multiple comparisons was used for post hoc analysis. D Treatment outcomes per cell line (mean + SD), grouped by their subtypes. To highlight the effects of Birinapant only, the single treatments and their corresponding co-treatment with Birinapant are shown. N = 3; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
